Misplaced Pages

Nidufexor

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound Pharmaceutical compound
Nidufexor
Identifiers
IUPAC name
  • 4-{pyrazole-3-carbonyl)amino]methyl}benzoic acid
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC27H22ClN3O4
Molar mass487.94 g·mol
3D model (JSmol)
SMILES
  • CN1C2=C(COC3=C2C=C(C=C3)Cl)C(=N1)C(=O)N(CC4=CC=CC=C4)CC5=CC=C(C=C5)C(=O)O
InChI
  • InChI=1S/C27H22ClN3O4/c1-30-25-21-13-20(28)11-12-23(21)35-16-22(25)24(29-30)26(32)31(14-17-5-3-2-4-6-17)15-18-7-9-19(10-8-18)27(33)34/h2-13H,14-16H2,1H3,(H,33,34)
  • Key:JYTIXGYXBIBOMN-UHFFFAOYSA-N

Nidufexor (LMB-763) is a drug which acts as a partial agonist of the farnesoid X receptor (FXR). It has reached Phase II clinical trials for the treatment of diabetic nephropathy and nonalcoholic steatohepatitis.

See also

References

  1. Chianelli D, Rucker PV, Roland J, Tully DC, Nelson J, Liu X, et al. (April 2020). "Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis". Journal of Medicinal Chemistry. 63 (8): 3868–3880. doi:10.1021/acs.jmedchem.9b01621. PMID 31940200.
  2. Fiorucci S, Biagioli M, Sepe V, Zampella A, Distrutti E (June 2020). "Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)". Expert Opinion on Investigational Drugs. 29 (6): 623–632. doi:10.1080/13543784.2020.1763302. PMID 32552182. S2CID 219911969.


FXRTooltip Farnesoid X receptor and LXRTooltip liver X receptor modulators
FXRTooltip Farnesoid X receptor
LXRTooltip Liver X receptor
See also
Receptor/signaling modulators


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: